Effectiveness and Safety of Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Third Interim Analysis of a German Non-Interventional, Prospective, Multicenter Study (ESCALATE-RA)

被引：0
|
作者：
Krueger, Klaus [1 ]
Prothmann, Ulrich [2 ]
Klopsch, Thilo
Behmer, Olaf [3 ]
Hsieh, Min-Jean [3 ]
Jobst, Juergen [3 ]
Klaus, Pascal [3 ]
Meng, Thomas [3 ]
机构：
[1] Praxiszentrum St Bonifatius, Rheumatol, Munich, Germany
[2] Knappschaftsklinikum Saar, Puttlingen, Germany
[3] Pfizer Pharma GmbH, Berlin, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0301
引用
收藏
页码：586 / 589
页数：4
相关论文
共 49 条
  • [21] The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study
    Witte, T.
    Kiltz, U.
    Haas, F.
    Riechers, E.
    Prothmann, U.
    Adolf, D.
    Holland, C.
    Rossler, A.
    Soppa, U.
    Fritz, B.
    Goetz, K.
    Kruger, K.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (03) : 726 - 735
  • [22] Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany
    Krueger, Klaus
    Burmester, Gerd R.
    Wassenberg, Siegfried
    Bohl-Buehler, Martin
    Thomas, Matthias H.
    [J]. BMJ OPEN, 2018, 8 (06):
  • [23] Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study
    Wassenberg, Siegfried
    Klopsch, Thilo
    Plenske, Anja
    Behnck-Knoblau, Silke
    Jobst, Juergen
    Klaus, Pascal
    Meng, Thomas
    Loeschmann, Peter-Andreas
    Rau, Rolf
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [24] Efficacy and Tolerability of Certolizumab pegol for the Treatment of rheumatoid Arthritis in clinical Practice in Germany: 3rd Interim Analysis of non-interventional Study "Fast"
    Burmester, G.
    Mueller-Ladner, U.
    Nuesslein, H.
    von Hinueber, U.
    Edelmann, E.
    Detert, J.
    Hoehle, M.
    Richter, C.
    Klopsch, T.
    Kumke, T.
    Fricke, D.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 100 - 100
  • [25] REAL-WORLD EFFECTIVENESS AND SAFETY OF APREMILAST IN BELGIAN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS FROM THE MULTICENTRE, PROSPECTIVE, NON-INTERVENTIONAL APOLO STUDY
    de Vlam, Kurt
    Nzeusseu, Adrien
    Kaiser, Marie-Joelle
    Vanhoof, Johan
    Remans, Philip
    Van den Berghe, Marthe
    Di Romana, Silvana
    van den Bosch, Filip
    Leroux, Sofie
    Vanhooff, Virginie
    Lories, Rik
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1837 - 1837
  • [26] Influence of the treatment of immune thrombocytopenia (ITP) with Eltrombopag on the fatigue symptoms of ITP patients - Results of the third interim analysis of the German non-interventional study RISA
    Meyer, O.
    Stauch, M.
    Kaempfe, D.
    Schlag, R.
    Reiser, M.
    Stauch, T.
    von der Heyde, E.
    Josting, A.
    Plath, M.
    Ballerstaedt, N.
    Stark-Lorenzen, P.
    Scheibenbogen, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 179 - 179
  • [27] EFFICACY OF ETANERCEPT ON RADIOGRAPHIC PROGRESSION IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIATIC ARTHRITIS: RESULTS FROM THE SECOND INTERIM ANALYSIS OF A GERMAN NON- INTERVENTIONAL, PROSPECTIVE, MULTI-CENTER STUDY
    Wassenberg, S.
    Rau, R.
    Klopsch, T.
    Buecheler, M.
    Meng, T.
    Loeschmann, P. -A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1259 - 1260
  • [28] Efficacy and safety data of the treatment with azacitidine in a routine care setting in germany; data from the first planned Interim analysis of the non-interventional study "Observational study on treatment patterns VIDAZA®"
    Platzbecker, U.
    Lueck, A.
    Prange-Krex, G.
    Lollert, A.
    Schwarzer, A.
    Schwinger, U.
    Uhlig, J.
    Bachinger, A.
    Weiligmann, C.
    Steudel, C.
    Illmer, T.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 252 - 252
  • [29] GOLIMUMAB AS FIRST, SECOND OR AT LEAST THIRD BIOLOGIC AGENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING SPONDYLITIS (AS) - POST HOC ANALYSIS OF A NON-INTERVENTIONAL STUDY IN GERMANY
    Krueger, Klaus
    Burmester, Gerd Ruediger
    Wassenberg, Siegfried
    Thiele, Astrid
    Thomas, Matthias
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1156 - 1157
  • [30] Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) - Post Hoc Analysis of a Non-Interventional Study in Germany
    Krueger, Klaus
    Burmester, Gerd
    Wassenberg, Siegfried
    Thiele, Astrid
    Thomas, Matthias
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345